News
Explore the latest stories and publications from NCATS and our partners, see upcoming events, or explore the variety of resources we provide to better understand translational science and our work.
News
Read the latest news from NCATS and its collaborators whose research is supported through the Center’s programs, or follow coverage of NCATS' translational research activities through national and local media.
Neuroimmune Signaling Between the Heart and the Brain May Contribute to Heart Attack Damage
April 10, 2026 - NCATS News
- Clinical and Translational Science Awards (CTSA) Program
NIH-funded researchers found a harmful triple-node loop involved in heart attacks. Blocking any one of these three components reduced heart injury and improved heart function.
Read ArticleWyss Institute Technologies Enable Breakthrough in Astronaut Health Research Aboard NASA’s Artemis II Mission
April 9, 2026 - Grantee/Partner News
- Tissue Chip for Drug Screening
Parkinson’s May Take a ‘Gut-First’ Path
September 6, 2024 - Grantee/Partner News
- Clinical and Translational Science Awards (CTSA) Program
New AI-Driven Tool Could Revolutionize Brain Pressure Monitoring in Intensive Care Patients
September 5, 2024 - Grantee/Partner News
- Clinical and Translational Science Awards (CTSA) Program
EU Roadmap : Key Recommendations, First Roadmap on OoC Devices, Awards to Non-Animal Methods, Artificial Organs Closer to Reality and More
September 4, 2024 - Grantee/Partner News
- Tissue Chip for Drug Screening
Brain Organoids Help Reveal Antiviral Drug’s Promise in Parkinson’s Disease
September 4, 2024 - NCATS News
NCATS scientists used organoids to test the antiviral tilorone as a potential treatment for Parkinson’s disease.
(MABT) and (Accelero) Are Pleased to Announce a Research Collaboration to Identify Novel USP30 Inhibitors
September 4, 2024 - Grantee/Partner News
- Small Business (SBIR)
NCATS-Developed Ketamine Alternative Didn’t Cause Dissociation
September 3, 2024 - NCATS News
- Chemistry Technology
- Our Impact on Drug Discovery and Development
NCATS scientists helped develop a version of ketamine that lacked sedative or dissociative effects in a phase 1 clinical trial.